Gilead Secures All Regulatory Approvals for Arcellx Acquisition, Extends Tender Offer
Summary
Gilead Sciences has announced it has received all required regulatory approvals for its acquisition of Arcellx, a significant step towards closing the deal. The company also extended its tender offer for Arcellx shares. This development follows the detailed disclosure of the $7.0 billion Arcellx acquisition in Gilead's 2025 10-K filing, indicating the transaction is progressing as planned. Securing regulatory clearance removes a major hurdle, reducing execution risk and providing clarity on the completion of this material acquisition. Traders will now focus on the successful conclusion of the tender offer and the final closing of the acquisition.
At the time of this announcement, GILD was trading at $139.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172B. The 52-week trading range was $93.37 to $157.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.